Eli Lilly’s Zepbound Outperforms Wegovy in Weight Loss Head-to-Head Trial

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisk’s Wegovy in a direct comparison across five key weight-loss metrics, including waist circumference reduction. Results from the first-ever head-to-head trial were presented at the European Congress on Obesity and confirmed Zepbound's superior efficacy.

Previously reported in December, the trial had already shown that Zepbound led to 47% more weight loss than Wegovy. According to full data released Sunday, nearly 25% more participants lost over 15% of their body weight with Zepbound compared to Wegovy.

The study revealed Zepbound users experienced an average waist reduction of 18.4 centimeters, versus 13 centimeters for those on Wegovy. Zepbound, which mimics two gut hormones, has a dual mechanism of action, while Wegovy targets just one. This biological advantage may explain the enhanced weight loss results.

Both drugs had previously received U.S. FDA approval based on separate clinical trials—Zepbound achieved over 22% weight loss after 72 weeks, while Wegovy showed 15% loss after 68 weeks. The obesity drug market is expected to surpass $150 billion annually by the next decade, making these results crucial as Eli Lilly seeks broader insurance coverage.

The new data comes shortly after CVS Health (NYSE:CVS) dropped Zepbound from some reimbursement lists in favor of Wegovy. However, these trial findings may bolster Lilly’s position in payer negotiations and strengthen its commercial appeal.

With growing demand for effective weight-loss treatments, Zepbound’s performance positions it as a formidable competitor in the fast-growing obesity drug market, challenging Wegovy’s dominance with robust clinical backing and enhanced patient outcomes.